New! Dexlansoprazole 60 mg Delayed-Release Capsules
Wexford Laboratories is proud to present its latest pharmaceutical innovation: Dexlansoprazole 60 mg delayed-release capsules, a proton pump inhibitor (PPI) widely recommended for the treatment of erosive esophagitis, as well as gastric and duodenal ulcers.
Patient Benefits
Our Dexlansoprazole offers multiple advantages for patients requiring effective treatment for gastroesophageal reflux disease (GERD) and other acid-related conditions. Key benefits include:
- Longer-lasting effect: Thanks to its dual-phase modified-release technology, it enables prolonged absorption of the active ingredient, ensuring sustained symptom relief.
- Consistent absorption and high tolerability: Its optimized formulation improves the drug’s bioavailability, ensuring effective action with fewer side effects.
- Flexible administration: Unlike other treatments, this medication can be taken with or without food, making it easier for patients to incorporate into their daily routine.
Differentiation and Competitive Advantages
Our Dexlansoprazole 60 mg is not only a highly effective treatment but also represents an excellent opportunity for market differentiation for our business partners. Its strong potential for growth in the pharmaceutical sector, combined with its therapeutic benefits, makes it an attractive option for laboratories seeking to offer innovative products in high demand.
Alu-Alu Blister Packaging: Optimal Product Protection
Understanding the importance of preserving the integrity and effectiveness of the medication, our Dexlansoprazole 60 mg is presented in Alu-Alu blister packs, a packaging format that offers:
- Maximum protection against moisture, oxygen, and light, ensuring the drug’s stability throughout its shelf life.
At Wexford Laboratories, we remain committed to developing cutting-edge pharmaceutical solutions that improve patients’ quality of life. Our Dexlansoprazole 60 mg delayed-release capsules, with their innovative mechanism of action and high-protection packaging, are a clear reflection of our dedication to excellence in the pharmaceutical industry.
Contact us now and be the first to register it!
Sources:
Dexlansoprazol: MedlinePlus medicinas. (n.d.). http://medlineplus.gov/spanish/druginfo/meds/a609017-es.html
Aluminio & Láminas Blister en la Industria Farmaceutica – Alfipa. (2024, June 11). Alfipa. https://alfipa.es/aplicaciones/aluminio-industria-farmaceutica/
